Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Adding ramucirumab to erlotinib treatment for patients with advanced non-small cell lung cancer with EGFR mutations

Posted by on Dec 20, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...

Read More

Safety and effectiveness of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer

Posted by on Dec 17, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.  This study concluded that this combination was found to be safe and promising in these patients.  Some background Pembrolizumab (Keytruda) is a targeted...

Read More

High neutrophil-to-lymphocyte ratio in patients with melanoma treated with PD-1 inhibitor

Posted by on Dec 9, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out if a high neutrophil-to-lymphocyte ratio (NLR) was related to the survival of patients with melanoma treated with PD-1 inhibitor treatment. The study found that the higher the NLR, the lower the chances of survival in these patients.  Some background One type of melanoma treatment involves...

Read More

Radiation therapy after surgery improves survival of patients with advanced colon cancer

Posted by on Dec 8, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of radiation therapy (RT) after surgery in patients with T4 (cancer that has grown outside of the colon outer layer and invades the surrounding tissues) colon cancer. Researchers suggested that RT improved overall survival in these patients. Some background Colorectal cancer is the third...

Read More

Palbociclib and exemestane versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer

Posted by on Dec 7, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.  This study concluded that palbociclib and endocrine therapy is more effective than...

Read More

Evaluating the outcomes of patients with advanced melanoma with different treatments

Posted by on Dec 7, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out how well patients with advanced melanoma treated with certain medications survived outside of clinical trials. The study found that patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) or patients treated with anti-PD1 antibodies had longer survival compared to those treated with BRAF/MEK...

Read More

Vitamin D is associated with improved survival outcomes of patients with advanced colorectal cancer

Posted by on Nov 29, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the association between vitamin D blood levels and survival outcomes in patients with metastatic colorectal cancer (mCRC). Researchers suggested that higher levels of vitamin D in the blood were associated with better survival. Some background CRC is the third most common cancer in the US. Among CRC patients, only...

Read More

Can bisphosphonates improve treatment outcomes for patients with lung cancer spread to the bones?

Posted by on Nov 3, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated whether zoledronate (Zometa) combined with TKI therapy is more effective than TKI therapy alone for patients with non-small cell lung cancer (NSCLC) spread to the bones. This study concluded that adding zoledronate to TKI therapy improved survival outcomes for these patients. Some background NSCLC is the most common...

Read More

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for HER2+ advanced breast cancer

Posted by on Nov 2, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which treatment resulted in better overall survival for patients with HER2+ breast cancer; trastuzumab emtansine (Kadcycla) with or without pertuzumab (Perjeta), or trastuzumab (Herceptin) plus a taxane. The study found that the overall survival was similar across...

Read More

A later introduction of anti-EGFR drug is as effective as the standard therapy for advanced colorectal cancer

Posted by on Oct 27, 2019 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of chemotherapy combined with bevacizumab (Avastin) or anti-EGFR drugs for treating advanced colorectal cancer (CRC). Researchers suggested that anti-EGFR later introduced in the treatment of these patients did not impact the outcomes of patients.  Some background CRC is the third most common...

Read More

Regular physical activity is associated with improved outcomes for advanced colorectal cancer

Posted by on Oct 20, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of physical activity (PA) on the outcomes of patients with advanced colorectal cancer. Researchers suggested that regular PA is associated with better outcomes for these patients. Some background Colorectal cancer is the third most common cancer worldwide. A significant number of patients...

Read More